FINWIRES · TerminalLIVE
FINWIRES

根據第一季業績,Stifel Canada維持對Alamos Gold的「買入」評等;目標價維持在80.00加幣。

By

-- 週四,在Alamos Gold(AGI.TO,AGI)公佈第一季業績後,Stifel Canada維持對該公司股票的「買入」評級和80.00加元的目標價。 Alamos公佈2026年第一季調整後每股收益為0.55美元,高於我們先前預測的0.53美元(與市場普遍預期0.55美元基本一致);調整後EBITDA為3.832億美元,高於我們先前預測的4.01億美元(市場普遍預期4.13億美元); 2026年第一季現金成本為每盎司1230美元,全部維持成本為每盎司1862美元,均高於先前指導的上限(分別為每盎司1200美元和1725美元),正如管理層此前所言,預計環比下降約5%,並在2026年下半年進一步改善。 2026年第一季自由現金流為1.017億美元,這意味著扣除營運資本後的每黃金當量自由現金流為每黃金當量1260美元(+130美元/黃金當量)。 (季增11.5%,而金價上漲722美元/盎司或漲幅達17.4%)。阿拉莫斯公司2026財年第一季末現金餘額為6.595億美元(季增3,600萬美元),淨現金為4.595億美元。此前,該公司以4,270萬美元的價格清償了約三分之一的Argonaut遺留對沖合約(1.5萬盎司,單價1821美元/盎司)。分析師拉爾夫·普羅菲蒂寫道:“公司重申2026財年業績指引,預計2026財年第二季度產量將環比增長17-25%,所有三個礦區均將有所貢獻,並預計2026財年下半年黃金產量將更加強勁。” (報告北美、亞洲和歐洲主要銀行及研究機構的股票、大宗商品和經濟研究。研究機構可透過以下連結與我們聯繫:https://www..com/contact-us

Price: $54.36, Change: $-1.57, Percent Change: -2.81%

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.

$FE
Sectors

Sector Update: Consumer

Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.

$LW
Australia

Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug

The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%

$AZN